Form 4: Arcutis Biotherapeutics Director Patrick J. Heron Reports Stock Purchases
SEC Form 4
Director Patrick J. Heron reports purchases of Arcutis Biotherapeutics stock through various entities and trusts.
Summary
- Patrick J. Heron, a director of Arcutis Biotherapeutics, reported purchasing shares of common stock through various entities.
- On May 13, 2025, 2,374 shares were purchased at a weighted average price of $13.7577.
- On May 14, 2025, 6,300 shares were purchased at a weighted average price of $13.7605.
- These purchases were made indirectly through Frazier Life Sciences X, L.P.
- Heron also indirectly owns shares through Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C.
- Additionally, Heron directly owns shares and indirectly owns shares through The Heron Living Trust 11/30/2004.
- Heron disclaims beneficial ownership of shares held by Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., and FHM Life Sciences VIII, L.L.C. except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock purchases by a director, which could be interpreted as a positive signal, but without additional context, it's difficult to gauge the overall impact.
Positives
- Director's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- The stock purchases by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 11/30/2004 | Date of The Heron Living Trust |
| 05/13/2025 | Date of first reported transaction: Purchase of 2,374 shares at a weighted average price of $13.7577 |
| 05/14/2025 | Date of second reported transaction: Purchase of 6,300 shares at a weighted average price of $13.7605 |
| 05/15/2025 | Date of signature on the Form 4 filing |
Keywords
Arcutis Biotherapeutics, ARQT, Patrick J. Heron, stock purchase, director, Frazier Life Sciences, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.